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Ibrutinib (PCI-32765) is an irreversible BTK (Bruton's tyrosine kinase) kinase inhibitor that has been extensively used as a tool compound to validate the role of BTK kinase in B cell related malignances. 1, 2 Ibrutinib has been shown in preclinical studies to inhibit the proliferation of diffuse large B-cell lymphoma cells, mantle cell lymphoma cells, chronic lymphocytic leukemia cells and multiple myeloma cells by blocking BTK kinase activity; ibrutinib was recently approved for the clinical application on mantle cell lymphoma and chronic lymphocytic leukemia cells. [3] [4] [5] [6] [7] Ibrutinib has also exhibited anti-inflammatory effects in preclinical models. 8, 9 Recently, it has been reported that ibrutinib is also effective against epidermal growth factor receptor mutantpositive non-small cell lung cancers through inhibition of epidermal growth factor receptor kinase activities. 10 In addition, there is evidence showing that BTK is also an important target for Acute Myeloid Leukemia (AML). 11 Despite the evidence that BTK knockdown impaired AML cancer cell growth, which suggested that BTK was important for AML cell proliferation, BTK kinase inhibition through use of a small molecule inhibitor like ibrutinib led only to moderate inhibition of proliferation of U937 cells with no apparent activity against other AML cell lines such as HL-60, TF-1 and THP-1. 11 To further investigate the potency and activity of ibrutinib against AML, we screened a panel of AML cell lines spanning M0-M7 disease stages. Interestingly, we found that only FLT3-internal tandem duplication (ITD) mutant AML cell lines (MOLM13, MOLM14 and MV4-11) were sensitive to ibrutinib (Figure 1a and Supplementary Table 1 ). This is similar to what has been observed with the highly Accepted article preview online 3 July 2015; advance online publication, 24 July 2015 potent and selective FLT3 inhibitor, AC220, but differs from that observed for the targeted BTK kinase inhibitor, CGI-1746. 12, 13 The selective antiproliferative activity was further confirmed in the clonogenic assay (GI 50 : 170-478 nM) (Supplementary Figure 1) . This suggests that ibrutinib might target FLT3 kinase in addition to BTK kinase.
We then investigated the effect of ibrutinib on FLT3-ITD mediated signaling in drug-sensitive cell lines. (Figure 1b Figure 2D) . Interestingly, despite the expression of the FLT3 wt kinase in all four cell lines, the induction of FLT3 auto-phosphorylation upon FLT3 ligand treatment was not observed in NOMO-1 and HL-60 cells like what was observed in the OCI-AML-3 and U937 cells, which might be due to the different genetic background and require further detailed mechanistic study. The FLT3 inhibitor AC220 demonstrated similar inhibitory activity to ibrutinib in FLT3-mediated signaling pathways in the FLT3-ITD positive cell lines. However, the BTK inhibitors, CGI-1746 and AVL-292, did not exhibit any effect on the signaling 14 ( Figure 2b and Supplementary Figure 2D ). As all of these cell lines express BTK kinase, we then studied the effect of ibrutinib on BTK signaling. Upon anti-immunoglobulin M (IgM) stimulation of B-cell receptor to active the BTK kinase signaling pathway, we found that only in the FLT3 wild-type (wt)-expressing cell lines (U937 and OCI-AML3), downstream mediators of BTK kinase were affected despite BTK phosphorylation having been inhibited in both FLT3 wt and FLT3-ITD cell lines. 9 This suggests that FLT3-ITD mutant cell lines might not rely on BTK signaling for growth (Supplementary Figure 3A) . Interestingly, except NOMO-1 and U937 cells, the phosphorylation of BTKY223 of MOLM14, MOLM13, MV4-11, OCI-AML-3 and HL-60 cells did not respond to anti-IgM stimulation apparently, which might be due to the basal-level expression of the IgM in these AML cells (Supplementary Figure 3B) . AC220 did not affect BTK kinase activity and its direct downstream target PLCγ but instead inhibited phosphorylation of protein kinase B and extracellular- signal-regulated kinase. The BTK inhibitors, CGI-1746 and AVL-292, were effective against BTK kinase and PLCγ kinase phosphorylation, but had no effect on the phosphorylation of protein kinase B and extracellular-signal-regulated kinase. These results suggest that ibrutinib may mainly exert its inhibitory activity through FLT3 kinase but not BTK kinase in the FLT3-ITD positive cells. To further confirm this, we knocked down BTK kinase in MOLM14 (FLT3-ITD), MOLM13 (FLT3-ITD), human erythroleukemia cell (HEL) (FLT3 wt) and NB4 (FLT3 wt) cells and found that the growth of MOLM14 and MOLM13 was only minimally affected; however NB4 cells were significantly inhibited and HEL cells were moderately inhibited (Figures 2a and b) . The fact that BTK knockdown in HEL cells did not lead to suppressed growth may be due to the fact that mutant JAK2 is the oncogenic driver in this cell line. 15 In addition, the finding that ibrutinib still significantly blocked the growth of BTK-knockdown MOLM14 and MOLM13 cells further validated that the growth inhibitory effect of ibrutinib is likely dependent mainly on FLT3-ITD inhibition. However, BTK kinase inhibition may also exert a combinatorial effect (Figure 2c ). It has recently been reported that BTK kinase is activated by FLT3-ITD in FLT3-ITD positive cell lines and dual inhibition of BTK and FLT3 kinase demonstrates combinatorial effects; these findings further confirm this observation. 16 Previous kinase selectivity profiling revealed that FLT3 wt might be an additional target of ibrutinib. 9 The biochemical ADP-Glo assay confirmed that ibrutinib has an IC 50 of 205.8 nM/65.65 nM against FLT3 wt and FLT3-ITD, respectively (Supplementary Figure 4A) . In the FLT3-ITD-dependent isogenic BaF3 cell line, ibrutinib demonstrated a GI 50 of 120 nM; this inhibitory effect could be completely rescued by interleukin-3 treatment (Supplementary Figure 4B) . Interestingly, it also potently inhibited the FLT3-D835H-BaF3 isogenic cell (GI50: 0.063 μM) and moderately inhibited FLT3-D835Y-BaF3 as well as TEL-FLT3-wt-BaF3 isogenic cells (GI50: 0.5 μM/0.46 μM), however was less active against ITD-D835Y, ITD-F691L and FLT3-K663Q mutations.
(Supplementary Figure 5A) In addition, ibrutinib did not affect the growth of other oncogene-expressing Ba/F3 cells, such as c-Kit, PDGFRα, BCR-ABL and NRAS (Supplementary Figure 5B) . Although there are cysteine residues in the ATP-binding pocket, binding mode examination with molecular modeling demonstrates that unlike the mode of inhibition against BTK kinase, ibrutinib inhibits FLT3 kinase through reversible binding and this is further confirmed by the washing-out experiment (Supplementary Figure 4C and D) .
Ibrutinib induced apoptotic cell death in a concentration-and time-dependent manner in FLT3-ITD cell lines but not FLT3 wtexpressing cell lines (Supplementary Figure 6) . Cell cycle analysis revealed that ibrutinib, but not the highly selective BTK kinase inhibitor, CGI-1746, could induce a concentration-dependent manner-arrest cells in G0/G1 phase (Supplementary Figure 7) . In addition, ibrutinib exhibited dose-dependent anti-proliferation activity against FLT3-ITD mutant-expressing primary patient cells but not FLT3 wt-expressing and multiple mutants such as FLT3-ITD/FLT3-D835Y and FLT3-D835Y/E mutants expressing samples, which further confirms that ibrutinib is FLT3-ITD selective (Figure 2d) .
AML still remains a serious unmet medical need and the FLT3-ITD mutant has been found in~30% of AML patients. Besides standard chemotherapy, there is no targeted therapy approved in the clinic to date despite several inhibitors that are presently under clinical investigation. 17 Currently, ibrutinib is under extensive clinical investigation against a variety of different B-cell malignancies. Given the fact that the safety profile of ibrutinib is tolerated in the patients, our results might help to expand the application of this drug to AML patients harboring the FLT3-ITD mutant.
Interestingly, despite the fact that the effective concentration of ibrutinib in the in vitro studies in the FLT3-ITD positive cell lines falls within the range of the peak plasma concentration used in human clinical trials (around 150 ng/mL at 560 mg/day dosage), the concentration required for the induction of apoptosis and cell cycle arrest for ibrutinib is higher, which suggests that an alternative formulation might be needed such as nano technology, to allow the increase of the plasma concentrations in the human patients while simultaneously retaining the safety profile for the potential clinical application. 18 Multiplexed targeted sequencing of recurrent fusion genes in acute leukaemia Dozens of recurrent chromosomal rearrangements have been described in acute leukaemia, where they often result in the fusion of two genes and in the expression of hybrid proteins. These genetic markers often delineate distinct clinical entities, and have been incorporated into the World Health Organization classification. Today, their evaluation at diagnosis thus provides crucial information for risk stratification, treatment decisions and residual disease evaluation.
1,2
Conventional cytogenetics is usually regarded as the gold standard method for the detection of these rearrangements. It is often considered mandatory at diagnosis but it requires a high level of expertise, is time consuming and is not suitable for the detection of many cryptic rearrangements. 3, 4 Complementary approaches, such as fluorescent in situ hybridization (FISH) and RT-PCR, are thus often needed, 5 but the cost of a comprehensive analysis can rapidly become prohibitive. Many markers that may provide important clinical information are therefore never tested, lowering the chances for the patients to benefit from the optimal treatments. To address this issue, we have developed a rapid and parsimonious ligation-dependent RT-PCR amplification assay (LD-RTPCR) 6 that allows for the detection of dozens of gene rearrangements (Figure 1 ).
We created a mix of 153 LD-RTPCR probes to target more than 50 recurrent fusion genes and three NPM1 mutations (Figures 1b  and c) . The procedure is detailed in Supplementary Methods, and representative results are provided in Supplementary Figure 1 . As shown in Supplementary Figure 2A , the results not only inform about the identity of the two partner genes, but also on the localisation of the breakpoint, guiding the choice of an appropriate assay for residual disease evaluation. The analysis of serial dilutions showed that~3.10 3 copies of transcripts are sufficient for the identification of the two partners (Supplementary Figure 2B) .
To validate this method, we applied it to a retrospective cohort of 540 patients treated in our institutions (Figure 2 and  Supplementary Table 2 ). Sixty-eight rearrangements were detected in 180 childhood ALL cases we tested. Fifty-two (76.5%) had been identified using RT-PCR at diagnosis and 20 (29.4%) using cytogenetics. Sixty-seven of these rearrangements (98.5%) were detected using LD-RTPCR. As expected in this cohort, the most common was the ETV6-RUNX1 fusion (33 cases), rearrangements of the MLL gene (eight cases, four with AFF1, two with MLLT1, one with AFF4 and one with MLLT3), 7 and the BCR-ABL1 (six cases), TCF3-PBX1 (five cases) and STIL-TAL1 fusions (four cases). 2 The LD-RTPCR assay only failed to detect one t(4;11) (q21;q23), which was identified at diagnosis using cytogenetics but could not be confirmed using RT-PCR. The breakpoint of this rearrangement may thus be unusual, or involve genes other than MLL and AFF1. It also validated four junctions, which were detected using cytogenetics, but which had not been verified using RT-PCR (one MLL-MLLT3, one MLL-AFF4 and two PICALM-MLLT10 8 fusions). Importantly, it revealed 11 additional rearrangements in this cohort, which had not been identified by either of the other methods: one MLL-MLLT1, two NUP214-ABL1, 9 five P2RY8-CRLF2 10 and three unusual rearrangements involving tyrosine kinase genes (ETV6-ABL1, ETV6-JAK2 and ZTBT6-ABL1).
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Forty-three abnormalities were detected in 93 adult ALL cases. As expected, the most frequent was the BCR-ABL1 fusion (30 cases). MLL fusions were found in eight cases (seven MLL-AFF1 and one MLL-MLLT1), and the others consisted of one ETV6-RUNX1, one STIL-TAL1, one SET-NUP214, one PICALM-MLLT10 and one P2RY8-CRLF2 rearrangement. Thirty-nine (90.7%) had been identified using RT-PCR at diagnosis and 36 (83.7%) using cytogenetics. All these abnormalities were detected using LD-RTPCR. Importantly, four fusions (SET-NUP214, 12 P2RY8-CRLF2, MLL-MLLT1 and PICALM-MLLT10) were detected only by this assay.
One-hundred and twenty-three abnormalities were detected in 237 adult AML cases, including 45 NPM1 mutations and 78 gene fusions. The most frequent involved the RARA gene (22 cases, with t(15;17)(q24;q21) and three t(11;17)(q23;q21)), and the MLL gene (19 cases). The others consisted of 16 CBFB-MYH11, 10 RUNX1-RUNXIT1, two NUP98-NSD1, 13 two BCR-ABL, one DEK-NUP214, 14 one KAT6A-CREBBP 15 and one PICALM-MLLT10 fusion. Fifty-four gene fusions (69.2%) had been identified using RT-PCR at diagnosis, and 61 (78.2%) using cytogenetics. Seventy-five of these abnormalities (96.2%) were detected using LD-RTPCR. One failure corresponded to a t(11;17)(q23;q21), where the involvement of RARA had been confirmed using FISH, but the involvement of ZBTB16 could not be validated using RT-PCR. The breakpoint may thus be unusual, or a partner other than ZBTB16 could be involved. The second corresponded to a t(11;17)(q23;q21) involving MLL, which had also been validated using FISH. All RT-PCR assays we tested failed to identify the second partner. The last failure corresponded to a PML-RARA fusion. Further analysis of this case revealed that the atypical genomic breakpoint occurred within the sixth exon of PML, which explains the failure of our assay. Importantly, the LD-RTPCR method revealed 16 new fusions in this cohort. Twelve corresponded to MLL fusions (11 partial tandem duplications (PTD) and one MLLT4), constituting nearly two-third of the MLL rearrangements in these patients. It also detected two Accepted article preview online 3 July 2015; advance online publication, 31 July 2015
